Comparing Two Chemotherapy Combinations for Lung Cancer
Author Information
Author(s): Passardi Alessandro, Cecconetto Lorenzo, Dall'Agata Monia, Dazzi Claudio, Pasquini Enzo, Oliverio Giovanni, Zumaglini Federica, Zoli Wainer, Nanni Oriana, Milandri Carlo, Frassineti Giovanni Luca, Amadori Dino
Primary Institution: Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy
Hypothesis
The study aims to evaluate and compare two treatment schedules for metastatic non-small cell lung cancer (NSCLC).
Conclusion
Both treatment schedules showed acceptable activity and survival outcomes as first-line treatments for NSCLC.
Supporting Evidence
- The objective response rate was 20% in arm A and 18% in arm B.
- Disease control rates were similar at 54% for arm A and 53% for arm B.
- Median survival was 32 weeks for arm A and 33 weeks for arm B.
Takeaway
Doctors tested two different ways to give chemotherapy to lung cancer patients and found both worked pretty well.
Methodology
Patients were randomized to receive either an experimental regimen or an empirical regimen every three weeks.
Limitations
The study only included stage IV patients, which may have influenced the outcomes.
Participant Demographics
The study included 81 patients with stage IV NSCLC, median age 63, with a balance of genders and performance statuses.
Statistical Information
Confidence Interval
95% CI: 10.0–35.9 for arm A and 95% CI: 8.6–33.9 for arm B.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website